Survival gain with re-Op/RT for recurred high-grade gliomas depends upon risk groups.
CONCLUSION: Re-RT after re-Op was tolerable with a cumulative median EQD2 of 99.3 Gy and resulted in clear benefit in PFS and marginal gain in OS. Survival gain with re-Op/RT was more prominent in patients with two or more risk factors (age ≥50, WHO pathologic grade IV, unmethylated MGMT promoter), and needs to be validated.
PMID: 29937212 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Chun SJ, Park SH, Park CK, Kim JW, Kim TM, Choi SH, Lee ST, Kim IH Tags: Radiother Oncol Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Chemotherapy | Conferences | Glioma | Neurology | Neurosurgery | Radiology | Study | Toxicology